Anke Meyer-Franke

Title: Anke Meyer-Franke: Innovator in Cell Death Inhibition

Introduction

Anke Meyer-Franke is a notable inventor based in Menlo Park, CA (US). She has made significant contributions to the field of biomedical research, particularly in the area of cell death inhibition. With a total of 2 patents, her work has the potential to impact treatments for various ischemic conditions.

Latest Patents

Meyer-Franke's latest patents include innovative compounds and methods aimed at inhibiting cell death. One of her patents focuses on bis-benzimidazole compounds and analogs that are effective in preventing apoptotic cell death. These pharmaceutical compositions are designed for the prevention and treatment of injuries associated with cell death, including conditions such as stroke, myocardial infarction, trauma, neurodegeneration, and inflammation. Another patent outlines a method for selecting compounds that treat ischemia-related cellular damage. This method involves screening for compounds that can reduce cellular damage in conditions like stroke or glaucoma, using primary cultures of excitable cells to determine their efficacy.

Career Highlights

Throughout her career, Anke Meyer-Franke has worked with prominent companies in the pharmaceutical industry, including Elan Pharma International Limited and Elan Pharmaceuticals, Inc. Her experience in these organizations has contributed to her expertise in developing therapeutic solutions for critical health issues.

Collaborations

Meyer-Franke has collaborated with notable colleagues, including Catherine M Bitler and Paul L Wood. These partnerships have likely enhanced her research and development efforts, leading to innovative solutions in her field.

Conclusion

Anke Meyer-Franke's work in the realm of cell death inhibition showcases her dedication to advancing medical science. Her patents and collaborations reflect her commitment to finding effective treatments for serious health conditions.